

DAFTAR PUSTAKA

1. World Health Organization. *WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment*. Geneva: WHO; 2019.
2. World Health Organisation. *Global Tuberculosis Report 2018*. Geneva: WHO; 2018.
3. Schorey JS, Schlesinger LS. Innate Immune Responses to Tuberculosis. *Microbiol Spectr*. 2016;4(6):1–27.
4. Amaral EP, Lasunskaja EB, Imp MRD. Innate immunity in tuberculosis: how the sensing of mycobacteria and tissue damage modulates macrophage death. *Microbes Infect*. 2016;18:11–20.
5. Mirsaedi M, Sadikot RT. Patients at High Risk of Tuberculosis Recurrence. *Int J Mycobacteriology*. 2018;7:1–6.
6. Lee J, Hartman M, Kornfeld H. Macrophage Apoptosis in Tuberculosis. *Yonsei Med J*. 2009;50(1):1–11.
7. Dietzold J, Gopalakrishnan A, Salgame P. Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop. *F1000Prime Rep*. 2015;7(29):1–8.
8. Behar, S. M.; Martin, C. J.; Booty, M. G.; Nishimura, T.; Zhao, X.; Gan HX. et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. *Mucosal Immunol*. 2011;4(3):279–287.
9. Dawson, David; Mohammed, Akhtar; Bretzel, Gisela; Boulahbal, Fadila; Dawson, David; Fattorini L et al. *Technical guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low Income Countries*. 5th ed. Paris: IUATLD; 2000.
10. Rajpal S, Dhingra VK, Aggarwal JK. Sputum grading as predictor of treatment outcome in pulmonary tuberculosis. *Indian J Tuberc*. 2002;49:139–142.
11. Hernandez-Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. *Thorax*. 2004;59(table 1):286–290.
12. Ravimohan, Shruthi; Kornfeld, Hardy; Weissman, Drew; Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *Eur Respirol Rev*. 2018;27(147).
13. Kementerian Kesehatan RI. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta: Kemenkes RI; 2014.

14. Kemenkes RI. *Peraturan Menteri Kesehatan Republik Indonesia nomor 67 tahun 2016 tentang Penanggulangan Tuberkulosis*. Jakarta: Kemenkes RI; 2016.
15. Mayer-Barber, Katrin D.; Andrade, Bruno B.; Barber, Daniel L.; Hieny, Sara; Feng, Carl G.; Caspar P et al. Innate and Adaptive Interferons Suppress IL-1 α and IL-1 β Production by Distinct Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection. *Immunity*. 2011;35(6):1023–1034.
16. Medzhitov R. Origin and physiological roles of inflammation. *Nature*. 2008;454(July):428–435.
17. Naidoo K, Dookie N. *Insights into Recurrent tuberculosis : Relapse Versus Reinfection and Related Risk Factors*. Intech Open; 2018.
18. Mcivor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. *Pathog Dis*. 2017;75:1–16.
19. Danial NN, Korsmeyer SJ. Cell Death : Critical Control Points Review. *Cell*. 2004;116:205–219.
20. Park JY, Pillinger MH, Abramson SB. Prostaglandin E 2 synthesis and secretion : The role of PGE 2 synthases. *Clin Immunol*. 2006;119:229–240.
21. Gil D, Garcia LF, Rojas M. Modulation of macrophage apoptosis by antimycobacterial therapy: Physiological role of apoptosis in the control of Mycobacterium tuberculosis. *Toxicol Appl Pharmacol*. 2003;190(2):111–119.
22. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. *J Infect Dis*. 2013;208(2):199–202.
23. Wecker L, Crespo LM, Dunaway G, Faingold C, Watts S. Prostaglandins and Other Eicosanoids. *Brody's Hum Pharmacol*. 2012:163–169.
24. Molnár M, Romero R, Hertelendy F. Interleukin-1 and tumor necrosis factor stimulate arachidonic acid release and phospholipid metabolism in human myometrial cells. *Am J Obstet Gynecol*. 1993;169(4):825–829.
25. Tran POT, Gleason CE, Poitout V, Robertson RP. Prostaglandin E2 mediates inhibition of insulin secretion by interleukin-1 β . *J Biol Chem*. 1999;274(44):31245–31248.
26. Lo CJ. Upregulation of cyclooxygenase-II gene and PGE 2 production of peritoneal macrophages in diabetic rats. *J Surg Res*. 2005;125(2):121–127.
27. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E.

- Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. *Investig Ophthalmol Vis Sci*. 2012;53(9):5906–5911.
28. Jia Z, Zhang Y, Ding G, Heiney KM, Huang S, Zhang A. Role of COX-2/mPGES-1/Prostaglandin E2 Cascade in Kidney Injury. *Mediators Inflamm*. 2015;2015:1–8.
 29. Nasrallah R, Hassouneh R, Hébert RL. PGE 2 , Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes. *J Am Soc Nephrol*. 2015;27(3):666–676.
 30. Nokta MA, Hassan MI, Loesch KA PR. HIV-Induced TNF- α Regulates Arachidonic Acid and PGE2 Release from HIV-infected Mononuclear Phagocytes. *Virology*. 1995;208(2):590–600.
 31. Almeida, M; Cordero, M; Almeida, J; Orfao A. Abnormal Cytokine Production by Circulating Monocytes and Dendritic Cells of Myeloid Origin in ART-Treated HIV-1+ Patients Relates to CD4+ T-Cell Recovery and HCV Co-Infection. *Curr HIV Res*. 2007;5(3):325–336.
 32. Wu D, Nikbin S. Mechanism of age-associated up-regulation in macrophage PGE 2 synthesis. *Brain, Behav Immun*. 2004;18:487–494.
 33. Cashman JN. The Mechanisms of Action of NSAIDs in Analgesia. *Drugs*. 2009;52(Supplement 5):13–23.
 34. Singh, Jasvinder A.; Saag, Kenneth G.; Bridges, S. Louis; Akl, Elie A.; Bannuru, Raveendhara R.; Sullivan MC. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2016;68(1):1–25.
 35. Holmberg BJ, Maggs DJ. The use of corticosteroids to treat ocular inflammation. *Vet Clin Small Anim*. 2004;34:693–705.
 36. Kuhn, Annegret; Bonsmann, Gisela; Anders, Hans-joachim; Herzer, Peter; Tenbrock, Klaus; Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. *Dtsch Arztebl Int*. 2015;112:423–432.
 37. Litow, Francesca K; Petsonk, Edward Lee; Bohnker, Bruce K; Carl, A. Brodtkin; Cowl, Clayton T; Guidotti TL et al. Occupational Lung Disease. *J Occup Environ Med*. 2015;57(11):1250–1254.
 38. Global Initiative for Asthma. *Global Strategy for Asthma Management and Prevention (2018 Update)*. (Hadfield R, ed.). GINA; 2018.
 39. Nishizaki, Yuji; Shimada, Kazunori; Tani, Shigemasa; Ogawa, Takayuki; Ando, Jiro; Takahashi M et al. Impact of smoking history on the association between Eicosapentaenoic acid to arachidonic acid ratio and acute coronary syndrome : A multicenter cross-sectional study. *Tob Induc*

- Dis.* 2018;16(8):1–6.
40. Amadio, Patrizia; Baldassarre, Damiano; Tarantino, Eva; Zacchi, Elena; Gianellini, Sara; Squellerio I et al. Production of prostaglandin E2 induced by cigarette smoke modulates tissue factor expression and activity in endothelial cells. *FASEB J.* 2015;29(9):4001–4010.
 41. Srinivasan L, Ahlbrand S, Briken V. Interaction of Mycobacterium tuberculosis with Host Cell Death Pathways. *Cold Spring Harb Perspect Med.* 2014;4(8):1–15.
 42. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. *Respir Res.* 2001;2(3):164–168.
 43. Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. *Infect Drug Resist.* 2011;4(1):129–135.
 44. Mariam, Deneke H; Mengistu, Yohannes; Hoffner, Sven E; Andersson DI. Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis. *Antimicrob Agents Chemother.* 2004;48(4):1289–1294.
 45. Agrawal, Monika; Bajaj, Ashish; Bhatia, Vinay; Dutt S. Comparative study of GeneXpert with ZN stain and culture in samples of suspected pulmonary tuberculosis. *J Clin Diagnostic Res.* 2016;10(5):9–12.
 46. Quest Diagnostic. Prostaglandin E2, Serum_Plasma Quest Diagnostics. (Online). 2019 (Cited 2019 June 10). Available from : <https://testdirectory.questdiagnostics.com/test/test-detail/91901/?cc=MASTER>.
 47. Pan Laboratories. Prostaglandin E2 - Pan Laboratories In-Vitro Diagnostic Testings. (Online). 2013 (Cited 2019 June 10). Available from : <http://panlaboratories.com/prostaglandin-e2/>.
 48. Ilavská S, Horvátová M, Szabová M, et al. Association between the human immune response and body mass index. 2012;73:480–485. doi:10.1016/j.humimm.2012.02.023.
 49. Dobner J, Kaser S. Body mass index and the risk of infection - from underweight to obesity. *Clin Microbiol Infect.* 2018;24(1):24–28. doi:10.1016/j.cmi.2017.02.013.
 50. Corona, ME J.; Garcia, L G.; DeRiemer, K.; Reyes, L. F; Del-Valle, M. B, Arellano BC. et al. Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area. *Thorax.* 2006;61:348–353.
 51. Horton KC, Macpherson P, Houben RMGJ, White G, Corbett EL. Sex

- Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries : A Systematic Review and Meta- analysis. 2016;21:1–23. doi:10.1371/journal.pmed.1002119.
52. Alavi-naini R, Sharifi-mood B, Metanat M. Association Between Tuberculosis and Smoking. *Int J High Risk Behav Addict*. 2012;1(2):1–4.
 53. Yen, Y-f; Yen, M-y; Lin, Y-s; Lin, Y-p; Shih, H-c; Li L et al. Smoking increases risk of recurrence after successful anti- tuberculosis treatment : a population-based study. *Int J Tuberc Lung Dis*. 2014;18(December 2013):492–498.
 54. Feng, Y; Kong, Y; Barnes, P F; Huang, F-f; Klucar, P; Wang X et al. Exposure to Cigarette Smoke Inhibits the Pulmonary T-Cell Response to Influenza Virus and Mycobacterium tuberculosis □. *Infect Immun*. 2011;79(1):229–237.
 55. Solá, Ernesto; Rivera, Carmen; Mangual, Michelle; Martinez J, Rivera K. Diabetes mellitus : an important risk factor for reactivation of tuberculosis. *Endocrinol Diabetes Metab Case Reports*. 2016;16(July):1–4.
 56. Garcia-Elorriaga G and DR-PG. Type 2 Diabetes Mellitus as a Risk Factor for Tuberculosis Mycobacterial Diseases. *J Mycobac Dis*. 2014;4(2):2–7.
 57. Yorke E, Atiase Y, Akpalu J, Sarfo-kantanka O, Boima V, Dey ID. The Bidirectional Relationship between Tuberculosis and Diabetes. *Tuberc Res Treat*. 2017;2017:1–6.
 58. Raghuraman S, P KV, Govindarajan S, Chinnakali P, Panigrahi KC. Prevalence of Diabetes Mellitus among Tuberculosis Patients in Urban Puducherry. *North Am J Medical Sci*. 2014;6(1):30–34.
 59. Ruslami R, Aarnoutse RE, Alisjahbana B, Ven AJAM Van Der. Implications of the global increase of diabetes for tuberculosis control and patient care. *Trop Med Int Heal*. 2010;15(11):1289–1299.
 60. Ricciotti E, A FG. Prostaglandins and Inflammation. *Arter Thromb Vasc Biol*. 2011;31(5):986–1000.
 61. Poole, E M; Hsu, L; Xiao, L; Kulmacz RJ, Carlson CS, Rabinovitch PS et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase and risk of colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*. 2011;19(2):547–557.
 62. Kumar NP, Moideen K, Nancy A, Viswanathan V. Plasma Eicosanoid Levels in Tuberculosis and Are Associated With Lung Pathology and Bacterial Burden. *Front Cell Infect Microbiol*. 2019;9(October):1–10.
 63. Chen YJ, Lee SS, Huang FM, Chang YC. Effects of nicotine on differentiation, prostaglandin E2, and nitric oxide production in

cementoblasts. *J Dent Sci.* 2015;10(4):431–436.

64. Kumar S, Jena L. Understanding Rifampicin Resistance in Tuberculosis through a Computational Approach. *Genomics Inform.* 2015;12(4):276.